2Lavanchy D. Hepatitis B virus epidemiology, disease burden, treamlent, and current and emerging prevention and control measures[J]. Viral Hepat, 2004,11 ( 1 ): 97-107.
3Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J]. Gastroentorology, 2003,125(9) : 1714-1722.
3Cheng JC,Wu JK, Lee PC, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation induced liver disease [J]. Int J Radiat Oncol Biol Plays, 2004,60(5) : 1502-1509.
4Asano N. Glycosidase inhibitors: update and perspectives on practical use[J]. Glycobiology,2003,13(10):93-104.
5Mehta A, Carrouee S, Conyers B, et al. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications [J]. Hepatology, 2001,33 (6) : 1488-1495.
6Ying C, De Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti hepatitis B virus activity in cell culture [J]. J Viral Hepat, 2000,7(1) : 79-83.
7Zoulim F. Therapy of chronic hepatitis B virus infection:inhibition of the viral polymerase and other antiviral strategies [J]. Antiviral Research,1999, 44(1): 1-30.
8Zitzmann N, Mehta AS, Carrouee S, et al. Iraino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus; implications for the development of broad spectrum anti-hepatitis virus agents [J]. Proc Natl Acad Sci USA, 1999,96(21):11878-11882.
